Insmed (NASDAQ:INSM) Coverage Initiated by Analysts at Cantor Fitzgerald

Cantor Fitzgerald started coverage on shares of Insmed (NASDAQ:INSM) in a research report released on Tuesday, Marketbeat Ratings reports. The brokerage issued an overweight rating and a $192.00 price target on the biopharmaceutical company’s stock.

INSM has been the topic of a number of other research reports. Evercore ISI reissued an “outperform” rating and set a $180.00 price objective on shares of Insmed in a report on Wednesday, October 1st. Mizuho lifted their target price on shares of Insmed from $130.00 to $165.00 and gave the company an “outperform” rating in a report on Wednesday, August 13th. Truist Financial lifted their target price on shares of Insmed from $126.00 to $139.00 and gave the company a “buy” rating in a report on Thursday, August 14th. Wells Fargo & Company began coverage on shares of Insmed in a report on Monday, October 20th. They issued an “overweight” rating and a $171.00 target price on the stock. Finally, William Blair began coverage on shares of Insmed in a report on Wednesday, August 20th. They issued an “outperform” rating on the stock. Nineteen analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $159.76.

Insmed Stock Up 0.8%

INSM stock opened at $165.29 on Tuesday. The company has a current ratio of 6.68, a quick ratio of 6.33 and a debt-to-equity ratio of 0.45. Insmed has a twelve month low of $60.40 and a twelve month high of $168.21. The company’s 50 day moving average is $148.88 and its two-hundred day moving average is $110.00. The stock has a market cap of $34.94 billion, a P/E ratio of -28.95 and a beta of 1.03.

Insmed (NASDAQ:INSM) last released its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported ($1.70) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.30) by ($0.40). Insmed had a negative return on equity of 195.37% and a negative net margin of 259.82%.The company had revenue of $107.42 million for the quarter, compared to analyst estimates of $104.06 million. During the same period in the previous year, the business posted ($1.94) EPS. The firm’s revenue for the quarter was up 18.9% compared to the same quarter last year. Insmed has set its FY 2025 guidance at EPS. Research analysts expect that Insmed will post -4.56 earnings per share for the current fiscal year.

Insider Transactions at Insmed

In related news, insider Orlov S. Nicole Schaeffer sold 76,520 shares of Insmed stock in a transaction on Friday, September 12th. The shares were sold at an average price of $145.45, for a total value of $11,129,834.00. Following the transaction, the insider directly owned 36,461 shares in the company, valued at $5,303,252.45. This trade represents a 67.73% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Michael Alexander Smith sold 24,272 shares of Insmed stock in a transaction on Tuesday, September 2nd. The shares were sold at an average price of $143.89, for a total transaction of $3,492,498.08. Following the completion of the transaction, the insider owned 54,902 shares in the company, valued at approximately $7,899,848.78. This trade represents a 30.66% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 152,657 shares of company stock worth $21,442,198 over the last quarter. 3.00% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Insmed

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. QRG Capital Management Inc. grew its position in Insmed by 15.6% in the 3rd quarter. QRG Capital Management Inc. now owns 6,420 shares of the biopharmaceutical company’s stock valued at $925,000 after buying an additional 864 shares during the last quarter. EULAV Asset Management purchased a new stake in shares of Insmed during the 3rd quarter worth $12,961,000. Cannon Global Investment Management LLC purchased a new stake in shares of Insmed during the 3rd quarter worth $648,000. Campbell & CO Investment Adviser LLC purchased a new stake in shares of Insmed during the 3rd quarter worth $2,745,000. Finally, Rakuten Securities Inc. boosted its position in shares of Insmed by 19,900.0% during the 3rd quarter. Rakuten Securities Inc. now owns 1,000 shares of the biopharmaceutical company’s stock worth $144,000 after purchasing an additional 995 shares in the last quarter.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.